menu
    • menu
    [{"orgOrder":0,"company":"Alumis","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"Alumis","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ AyurMaya","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ AyurMaya"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Alumis

    Menu

    Alumis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alumis, Kaken Partner on ESK-001 for Dermatology in Japan

                            Details : The collaboration aims to develop, manufacture and commercialize ESK-001, a highly selective, next-gen oral TYK2 inhibitor, for dermatology indications in Japan.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : $40.0 million

                            March 25, 2025

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

                            Details : A-005 is a potential first-in-class, brain penetrant tyrosine kinase 2 (TYK2) inhibitor being developed for the treatment of multiple sclerosis (MS), Parkinson’s Disease.

                            Product Name : A-005

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 19, 2024

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alumis Initiates ONWARD Phase 3 Program for ESK-001 in Plaque Psoriasis

                            Details : An oral, allosteric TYK2 inhibitor called ESK-001, is being investigated into phase 3 clinical trial for the treatment of moderate to severe plaque psoriasis.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alumis Announces Pricing of Initial Public Offering

                            Details : The net proceeds from the offering are intended for the development of its lead asset, an allosteric TYK2 inhibitor called ESK-001, into multiple phase 3 trials in moderate to severe plaque psoriasis.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Therapy developer Alumis prices U.S. IPO at about $902M

                            Details : The proceeds will fund clinical development for company's product candidates, including ESK-001, a TYK2 inhibitor currently in clinical development for moderate to severe plaque psoriasis and SLE.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Foresite Capital

                            Deal Size : $259.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Alumis Secures $259M Series C Financing for Immune Dysfunction Therapies

                            Details : Alumis will use the financing proceeds to begin Phase 3 clinical trials for ESK-001, a highly selective allosteric TYK2 inhibitor, developed for moderate to severe plaque psoriasis patients.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Foresite Capital

                            Deal Size : $259.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alumis Doses First Participant in Phase 1 Trial of CNS TYK2 Inhibitor A-005

                            Details : A-005 is a potential first-in-class CNS penetrant tyrosine kinase 2 inhibitor being developed for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and parkinson’s disease.

                            Product Name : A-005

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 30, 2024

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS

                            Details : A-005 is a potential first-in-class TYK2 inhibitor for treating multiple sclerosis, Parkinson’s Disease, and other neuroinflammatory diseases.

                            Product Name : A-005

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : A-005

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : AyurMaya

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advanc...

                            Details : Proceeds from the financing will be used to continue to advance Alumis’ pipeline, led by ESK-001, a highly selective and potentially best in class TYK2 inhibitor with greater selectivity for TYK2 over JAK1 compared to current therapies in clinical deve...

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 01, 2022

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : AyurMaya

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Alumis

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Foresite Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases

                            Details : Esker’s pipeline is led by ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1 compared to current therapies in development.

                            Product Name : ESK-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 05, 2021

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Foresite Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth